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Abstract 
Peppermint (Mentha x piperita L.) is a medicinal plant with significant pharmacological 
and therapeutic activities but side effects and detrimental impacts on health have been 
described. Herein, we studied the literature concerning the reported inherent toxicity of 
peppermint. Accordingly, we classified peppermint and its main constituents in acute, 
subacute, chronic, developmental toxicity and cytotoxicity studies. The review outcome 
revealed that peppermint and its main constituents (pulegone, menthone, menthol and 
menthofuran) exhibit some evidence of moderate toxicity. Peppermint and its menthol 
isomers possess no major innate mutagenic, genotoxic or embryotoxic properties. 
However, there is evidence that peppermint essential oil interacts appreciably with 
cytochrome P450 isoenzymes to reduce or prevent their activities in rat and human liver 
microsomes and this has a substantial clinical implication for drug metabolism. Moreover, 
peppermint essential oil is contraindicated in patients with bile duct obstruction, gall 
bladder inflammation and liver disorders. In patients with gastrointestinal reflux or hiatus 
hernia, its use should be exercised with caution because it may exacerbate the symptoms 
of gastrointestinal reflux. 
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1. Introduction  
Medicinal plants and herbal medicines have always played an important role in preventing 
and treating diseases throughout the world.
1,2
 Many medicinal plants have remedial effects 
but are not always safe and may be capable of causing toxicity.
3,4
 Based on the data from 
European and Brazilian poison centers gathered between 2006 and 2010, Mentha x 
piperita was reported as one of the ten most frequently used plant foods that caused 
adverse effects.
5 
M. x piperita L. is an ancient herbal medicine 
6,7
which is a natural interspecific hybrid of 
spearmint (M.  spicata L.) and water mint (M. aquatica L.).
8-11
 The common name for M. 
x piperita is Peppermint. It is also commonly known as Nana, Brandy mint, Candy mint, 
Lamb mint or Balm mint all over the world.
7,9
 Peppermint is a perennial, glabrous, 
strongly scented herb belonging to the Lamiaceae family.
12
 Plants of this family are often 
used in traditional medicine for phytotherapy.
13,14 
Peppermint is a fast spreading, herbaceous rhizomatous, winter hard plant with square 
cross sectional smooth stems which usually grow to a height of 30–90 cm. The rhizomes 
are widespread and fleshy with fibrous roots.
9 
The leaves are the most important part of 
the plant from which oil is extracted.
7
 They are 4–9 cm in length and 1.5–4 cm broad 
being dark green in color with reddish veins, having an oblong-ovate shape with an acute 
apex and coarsely toothed margins (Figure 1). Both the leaves and stems are slightly hairy. 
The flowers are purple-pinkish, 6–8 mm long, with a four-lobed corolla of approximately 
5 mm diameter which usually appears in the summer months. The chromosome number is 
variable, with 2n counts of 66, 72, 84, and 120.
9,15 
The peppermint herb is native to Mediterranean Europe, naturalized in the northern USA 
and Canada but currently cultivated all over the world. It grows well in moist, shaded 
areas, with high water holding capacity soil.
8,16  
Peppermint is used in various forms such as the essential oil and leaf extract. All the 
varieties have many uses, but the essential oil has the highest degree of general 
consumption
11,17
  and its global production amounts to about 8000 tons per year .9 The 
FDA banned the sale of peppermint essential oil over-the-counter as a digestive aid as early as 
1990 because of unproven effectiveness and nowadays, peppermint is sold as a dietary 
supplement.
18
  
The chemical constituents of M. x piperita are comprised of monoterpenoids, the main 
components of its essential oil. These include menthol (29-48%), menthone (20-31%), 
menthofuran (6-8%), pulegone, menthyl acetate (3-10%), limonene, pinene and piperitone 
in addition to caffecic acid, flavonoids like luteolin and menthoside, polyphenols including 
rosmaric acid, carotenes, tocopherols, narirutin, eriodictyol, tannins, betaine and 
choline.
6,7,9,15
 An active component of peppermint essential oil which has also been 
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highlighted in many studies as a key ingredient of the plant, is menthol but it also contains 
other constituents such as its biosynthetic precursor pulegone and its metabolites 
menthone and menthofuran (Figure 1).
19-23
   
Peppermint essential oil is currently used in the cosmetic, personal hygiene, food, 
beverage, pharmaceutical products and perfumery industries as a flavouring agent and for 
its fragrance properties.
9,24,25
 Also, currently it is used widely as flavoring in ice cream, 
chewing gum, cigarettes, breath freshener, mouthwash, toothpaste, dental floss, 
confections, and tea.
11,16
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Figure 1. Biosynthetic pathway of some monoterpinoids in M. x piperita showing the 
precursor (+)-Pulegone (originally derived from (-)-Limonene) and the products (-)-
Menthone, (-)-Menthol and the non-terpenoid (+)-Menthofuran
22
 as the main active 
constituents of peppermint essential oil.
23 
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Over recent years it has been demonstrated that both peppermint and its constituents 
induce antioxidant, antispasmodic, aromatic, antimicrobial, antibacterial, antiviral, 
anticarcinogenic, antitumorigenic, antiallergic, antiinflammatory, antifungal, 
antimutagenic, anticancer, antinauseant, antiseptic, antilipid peroxidation, antiheadache 
and antiobesity properties.
7,9,23,26-32
  
Menthol is well absorbed by the oral route in rats (63% - 74%) and rabbits (86% - 
90%).
33,34
 and at ≤90%, this level is predictably much higher than that yielded by dermal 
absorption.
35
 Subsequently, Clegg and coworkers disclosed that [
3
H]-menthol was 
distributed in the urine, feces, ileum, fat, liver, serum, kidney, brain and testes.
36
  
Menthol is normally metabolized in the liver to menthol glucuronide.
34,37
  as the main 
biliary metabolite 
34,37
 and it is excreted in the urine and feces.
33,34,36
  The other urinary 
metabolites consist of mono- or di-hydroxylated menthol derivatives that are eliminated as 
glucuronic acid conjugates.
37 
In humans, menthol is excreted as the glucuronide in the 
urine within 12 to 24 hours after oral consumption.
38-40
  (+)-Pulegone is metabolized to (-
)-menthone by (+)-pulegone reductase in the cytosol and then further reduced by cytosolic 
(-)-menthone reductase to (-)-menthol. (+)-Menthofuran is also generated by conversion of 
(+)-pulegone in the endoplasmic reticulum via the enzyme (+)-menthofuran synthase 
(Figure 1).
22,23
 
In the case of peppermint, it modulates the enzymes of phase I and phase II metabolism
41
 
which play an important role in biotransformation or inactivation of endogenous 
compounds and xenobiotics.
42 Additionally, peppermint has been shown to ameliorate the 
harmful effects of carbon tetrachloride on liver function.
43
 Despite the widespread use of 
peppermint as a medicinal plant in many countries, there has been no truly comprehensive 
recent overall scrutiny categorizing its toxic effects in vitro and in animal and human 
studies. In view of this situation therefore, the current review was undertaken to evaluate 
the literature on the acute, sub-acute, and chronic toxicity of peppermint and its main 
products, with a focus on any possibility of induction of direct toxicity and/or 
developmental and mutagenic detriment. 
 
 
2. Method 
A comprehensive literature search was performed on scientific databases including: 
PubMed, Scopus, Google Scholar and Science Direct. The relevant key words used as 
search terms were: “Mentha piperita”, “peppermint”, “menthol”, “pulegone”, “menthone”, 
“menthofuran”, “chronic toxicity, sub-chronic toxicity, sub-acute toxicity, acute toxicity, 
mutagenicity, genotoxicity” and “developmental toxicity”. Relevant full papers and 
abstracts were retrieved, then the reference lists of the key papers for further evaluation 
were searched and both in vitro and in vivo investigations were incorporated.  
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The toxic effects of peppermint were categorized and assigned to the following main 
headings of the toxicological findings: mutagenicity, genotoxicity, cytotoxicity, 
hepatotoxicity, carcinogenicity, embryotoxicity/developmental toxicity, carcinogenicity, 
clinical and preclinical toxicity. 
 
3. Toxicological findings 
A range of side effects have been reported regarding medicinal plants and natural 
products. These toxicological properties may occur by different mechanisms which 
include direct toxicity, contamination and pharmacological interactions with drugs and/or 
other herbs.
44
  
In this particular context, the four prime potentially toxic compounds which have been 
identified in peppermint are menthol, pulegone, menthone and menthofuran.
9
 Also, it 
should be noted that in the case of peppermint, the extraction method can affect the 
essential oil concentration. A distinctive example of this is selective ohmic-assisted 
hydrodistillation as compared to traditional hydrodistillation which produces variation in 
the chemical composition of extracted essential oils
45
 and this may well influence the 
toxicological outcome of the extract. 
3.1. Acute toxicity 
The primary toxicity test of any chemical substance is invariably performed acutely and 
the median lethal dose or LD50, as a method of assessment, has been employed historically 
for many years in this regard. However, in recent years more acceptable methods of 
evaluation have been pursued.
46
 Nonetheless, in the LD50 test, interspecies sensitivity, 
after single exposure to a chemical substance is initially observed routinely for 14 days.
47
 
Many factors such as animal age, weight, strain and diet influence the LD50 outcome value 
and rats and mice are the most commonly used species in the test.
47-49
 Arising from LD50 
values accumulated over time, toxicity levels of chemicals have been categorized into five 
different classes as follows: dangerously toxic (<1.0 mg/kg), extremely toxic (1-50 
mg/kg), very toxic (50-500 mg/kg), moderately toxic (500-5000 mg/kg), slightly toxic 
(5000-15000 mg/kg) and practically non-toxic.
50 
LD50 values have been reported for peppermint essential oil at varying doses in the range 
2410 – 4441 mg/kg in rats.20,51,52 Whereas in mice, an LD50 >1600 mg/kg has been 
documented for peppermint oil
24
 and at an acute dose of 0.2 ml/kg, it has not only been 
shown to prolong pentobarbitone-induced sleeping time but also to chronically potentiate 
midazolam motor incoordination.
17
  
Menthol isomers (L-menthol, D-menthol and D/L-menthol) present in peppermint oil
24
 
have been shown to produce low acute oral toxicity with LD50 values typically >2000 
mg/kg in rats and mice.
53
 However it is noteworthy that these isomers did produce local 
irritancy to the eye, skin
53
 and respiratory tract
54
 though intraspecies studies generally 
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suggested there was low sensitizing activity by a variety of routes
55
 (Table 1). Menthol 
also has insecticidal activity and in this respect, it is not only mosquitocidal
56
 but it also 
acts as a fumigant with ovicidal activity against houseflies.
23,57  
  
 
Allergic contact dermatitis has been reported to herbal remedies using patch testing.
58
 The 
action of L-menthol and D/L- menthol on patients with different skin conditions such as 
dermatoses, eczematous lesions, contact dermatitis and mucosa/skin reactions may evoke 
sensitivity reactions (0-6.1%). Nevertheless, the overall, sensitizing effect of menthol 
isomers has tended to be generally low
59-62
 or even non-existent.
63
  
High doses of the monoterpene ketone, pulegone, as well as menthofuran in the herb 
pennyroyal (M. pulegium), have been reported to be abortifacient.
23,64
 Pulegone also 
possesses insecticidal toxicity against houseflies, cockroaches, rice weevils and 
earthworms.
65
 Menthone and menthofuran, on the other hand, have both been shown to 
cause an increase in liver weight, hepatotoxicity and cerebellar pathology even in the 
short-term.
66,67
 Additionally, menthofuran has been described as causing pediatric multiple 
organ failure
68
 and as a metabolite of pulegone, it may well contribute appreciably to the 
overall toxicity of the parent pulegone.
69 
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Table 1. Acute toxicity findings with peppermint and its main constituents. 
Compound Species Main finding Reference 
 
  Peppermint 
  essential oil 
Human 
Overdose coma/hypoxemia, severe 
hypotension and shock 
70 
 
Peppermint 
essential oil 
Mouse 
 
LD50 = 1612.45 mg/kg 
 
24 
 
Peppermint 
essential oil 
Rabbit 
Respiratory harm 
 
71 
 
 
Menthol 
Human 
Coma, convulsions, hematuria, fatality 
 
72 
Menthol Rat/Mouse LD50 = 2046-2615 mg/kg 53,73 
Menthol 
Mouse 
 
Respiratory tract irritation (16 ppm) 
 
54 
 
Menthol Insects Mosquitocidal 56 
Menthol Insects 
House fly Fumigant/Ovicidal 
 
23,57 
 
 
Pulegone 
 
Human 
Paediatric multiple organ    failure 
(Pulegone in pennyroyal/M. pulegium) 
 
68 
Pulegone 
 
Human 
Hepatotoxicity (Pulegone in 
pennyroyal/M. pulegium) 
 
67 
 
Pulegone 
 
Human 
Abortifacient 
(Pulegone in pennyroyal/M. pulegium) 
 
64 
 
Pulegone 
 
Rat 
 
Hepatotoxicity 
 
74 
Pulegone 
 
Rat 
≤600mg/kg Hepatotoxicity/lethality 
 
20,75 
Pulegone 
 
Insects 
House fly fumigant/ovicidal 
 
23,57 
 
Menthone 
 
Rat 
Hepatotoxicity and cerebellar 
pathology 
 
66 
Menthone 
 
Rabbit 
Intradermal Moderate/severe reactions 
 
20 
 
Menthofuran 
Human 
 
Hepatotoxicity 
(Menthofuran in pennyroal/M. 
pulegium) 
 
67 
Menthofuran 
Human 
 
Pediatric multiple organ failure 
(Menthofuran in Pennyroyal/M. 
pulegium) 
 
68 
Menthofuran 
Human 
 
Abortifacient 
(Menthofuran in pennyroyal/M. 
pulegium) 
 
64 
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Peppermint essential oil, menthol, pulegone and menthone, but not menthol,
76
 have been 
reported to create cyst-like spaces in rat cerebellar white matter.
66,77
 However, later 
independent evaluation deduced that these pathological findings were likely to be artefacts 
originating from the method of tissue preparation and fixation.
78,79
  
 
 
3.2. Subacute toxicity 
Subacute toxicity is described as the effects of a specific substance that is administered at 
three to four different dosages to animals repeatedly over a period of 14-28 days of 
exposure. The results and information derived about the toxicity of a substance may then 
be used to determine doses for sub-chronic studies.
47,48
 Thus, in this frame of reference, L-
menthol has been administered in mice sub-acutely (2000-5000 mg/kg) by gavage for 5-14 
days and the LD50 was subsequently determined as 2600 mg/kg.
53
  
 
3.3. Sub-chronic toxicity 
Sub-chronic toxicity tests are usually conducted in both sexes of rats, mice and dogs. 
Substance administration (at least three doses) is carried out for 30-90 days. The no 
observed adverse effect level (NOAEL), lowest observed adverse effect level (LOAEL), 
respiratory and cardiovascular functions, biochemical and hematological parameters, body 
weight, and food consumption are then recorded. The results of the sub-chronic test at that 
juncture are used to establish doses suitable for later chronic studies.
47,50
  
Sub-chronically administered peppermint oil (100 mg/kg per day for 90 days) in rats is 
known to cause nephropathy (hyaline droplet formation) and cyst-like spaces scattered 
throughout the white matter of cerebellar tissues.
20,77
 Despite this finding, there is no 
evidence that either encephalopathy or epithelial degeneration occurs in the brain.
80
  
Analogously, B6C3F1 mice exposed to daily DL-menthol for 13 weeks exhibited a 
decrease in body weight and Fischer 344 rats treated for the same period displayed 
spontaneous interstitial nephritis (Table 2).
53
 In another investigation regarding 
inhalational toxicity, Sherman rats were exposed to vaporized L-menthol and transient 
conjunctival erythema, tracheitis, pulmonary congestion, pneumonitis and severe 
congestion to pneumonitis, were described although exposure concentrations were not 
presented.
53,81
  
In a study using rats, pulegone was administered by gavage at a dose of 160 mg/kg and 
there was a decrease in food consumption and body weight but no cerebellar pathology 
was observed. However, liver weight and plasma alkaline phosphatase were increased 
which was suggestive of an adverse hepatic effect.
82
 In contrast, menthone toxicity has 
been described following sub-chronic treatment
75
 but no adverse effects were detected 
when menthofuran was presented in the diet.
83
  
11 
 
 
3.4. Chronic toxicity 
 The duration of chronic toxicity testing normally involves longer than 3-months of 
exposure, although it tends to be extended in rodents (six months to two years) and non-
rodents (one year or longer). Chronic toxicity studies are employed to evaluate the 
maximum tolerable dose, urinary metabolite indexes and physiological as well as 
pharmacokinetic aspects of the chemicals under test.
47 
There are no available reports on the chronic toxicity of peppermint in humans. However, 
high concentration exposure to menthol vapor has been shown not to induce chronic 
toxicological effects in rats.
84
 Notwithstanding this, Fischer 344 rats receiving daily doses 
of D/L-menthol for 103 weeks, disclosed renal inflammation in the males but decreased 
mammary gland fibroadenomas in females
85
 (Table 2). Pulegone in a two-year study 
however, did cause fatality in mice and rats.
86
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Table 2.  Sub-chronic and chronic toxicity findings for peppermint and its main 
constituents 
Compound Species Findings Reference 
Peppermint   
essential oil 
Rat 100 mg/kg per 
day for 90 days 
Nephropathy 80 
 
 
Menthol 
 
Human 
(4 days exposure) 
Coma, convulsions, 
hematuria, fatality 
 
72 
Menthol 
 
Human 
20 years 
 
Coma and ataxia 
87 
 
Menthol 
 
Mouse 
(3913 or 4773 
mg/kg/day) for 13 
weeks 
Body weight decrease 53 
Menthol 
 
Rat 
(937 and 998 
mg/kg/day) for 13 
weeks 
Spontaneous 
interstitial nephritis 
53 
Menthol 
 
Rat 
(188 or 375 
mg/kg/day) for 103 
weeks 
 
Renal inflammation 
in males and 
decreased mammary 
gland fibroadenomas 
in females 
85 
Pulegone 
Rat 
Oral - 28 days 
 
NOEL 
<160 mg/kg/day 
 
82 
 
Pulegone 
Rat 
2-years 
75mg/kg 
Fatality 
 
86 
Pulegone 
Mouse 
2-years 
 
150 mg/kg 
Fatality 
 
86 
 
Menthone Rat (sub-chronic) 
200 mg/kg/day 
toxicity 
75 
Menthofuran 
Rat (23 mg/kg) 
14-day dietary 
No adverse effect 83 
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3.5. Mutagenicity, genotoxicity, cytotoxicity, hepatotoxicity, carcinogenicity, 
embryotoxicity/developmental toxicity studies. 
Adverse effects of medicinal plants on the development of organisms from the time of 
chemical or physical agent exposure at the pre-natal or post-natal stage up to the time of 
puberty are studied in developmental toxicity tests. Developmental toxicity includes 
growth retardation, structural malformations, functional or metabolic impairment and 
death of the organism. A component of developmental toxicity studies is reproductive 
toxicity which is intended to determine the adverse effects of substances on the male and 
female reproductive system. Correspondingly, substances that have developmental toxicity 
effects on the fetus are designated as teratogens.
47,49 
  
Data concerning the conceivable mutagenicity, genotoxicity, carcinogenicity, and 
developmental toxicity of peppermint and its constituents are summarized in Table 3. In 
vitro, the results of the Ames test for peppermint oil against Escherichia coli (WP2 uvrA) 
and bacterial strains of Salmonella typhimurium (including: G46, TA92, TA94, TA97, 
TA97a, TA98, TA100, TA102, TA1535, TA1537 and TA2637) did not manifest any 
evidence of mutagenicity.
20,88-96
 Also, in the mouse lymphoma mutation test, D/L-menthol 
(150 µg/ml) was not mutagenic in L5178Y tk+/- mouse lymphoma cells.
97
 Conversely 
however, peppermint did possess mutagenic effects in Drosophila melanogaster.
98,99
  
In other studies, D/L- and L-menthol effects have been investigated in Chinese hamster 
ovarian cells, human peripheral lymphocytes, human embryonic lung cells and human 
TK6 lymphocytes. It was conspicuously clear that none of these studies revealed any 
significant increase in polyploidy or numbers of aberrations in any of the assays.
100-103
 
Moreover, the single cell comet assay on D/L-menthol cytotoxicity and genotoxicity in 
Chinese hamster ovary K5 cells revealed an identical absence of positive activity.
104
 The 
possible mutagenicity of menthol in other investigations such as Bacillus subtilis anaphase 
chromosome aberration in the carcinoma prediction assay in C3H/10T1/2 cells carrying 
bovine papilloma virus DNA (D/L-menthol), human tissue culture cells (fibroblasts),
105
 
umu DC-lacZ genes in the Salmonella typhimurium strain TA1535/pSK1002,
106
 also have 
not divulged any explicit mutagenic propensity. Conversely, the in vitro alkaline 
elution/rat hepatocyte assay which is an important test for genotoxicity, has indicated that 
D/L-menthol is genotoxic.
107
 Furthermore, peppermint essential oil (0.30 µl/ml) generated 
sister chromatid exchange in human lymphocytes and induced chromosomal 
aberrations.
108
 It also prevented cell replication and the mitotic activity of human 
lymphocytes. The essential oil of this herb therefore is clastogenic but it is not a typical 
elastic clastogen because it has a mutagenic effect on Drosophila melanogaster somatic 
mutation (0.20 µl/ml).
96,98,109
  
Several in vivo studies have examined the effects of oral D/L-menthol in the comet assay 
in mice and all of them concluded that it was not mutagenic.
110-113
  Nonetheless, in a 
14 
 
replicative DNA synthesis test in B6C3F1 mice and F344 rats, D/L-menthol did display 
mutagenic effects at a low dose after 24 hours and at a high dose after 39 hours.
111,112
 
Interestingly, peppermint essential oil exhibited no mutagenicity in the 
Salmonella/mammalian-microsome test even though menthone by itself, which is present 
at 33.7% in the oil, was detected as a mutagen.
88
  
Antigenotoxicity effects of M. x piperita leaf extracts have been studied and they were 
found to reduce not only radiation induced chromosomal aberrations but also micronuclei 
in bone marrow cells from Swiss albino mice.
12,114
 In addition, it was later confirmed by 
the same research group, that peppermint was a chemopreventive antigenotoxic agent in 
benzo[a]pyrene-treated animals.
115 
In early studies concerning peppermint oil carcinogenicity, mice were dosed with 4-16 mg 
of oil/kg/day by gavage, for 6 days per week over 80 weeks. Animal body weights were 
subsequently decreased but there was also evidence of concomitant lung, kidney and 
hepatocellular carcinoma as well as malignant lymphoma.
20,116
 In overall contrast, in 
another contemporary investigation, peppermint essential oil was basically shown to be 
cytotoxic on human lymphocytes.
96
 In addition, the oil has also been examined in prostate 
(LNCaP) and breast cancer (MCF-7) cell lines using the MTT test and a distinct potential 
for cytotoxicity was identified in both cell culture models.
117
  
A more recent study on peppermint cytotoxicity was performed on human cancer cell lines 
(lung carcinoma cell line SPC-A1, leukemia cell line K562 and gastric cancer line SGC-
7901) and IC50 values were reported as 10.89, 16.16 and 38.76 mg/ml respectively.
118
 
Peppermint has similarly been shown to prevent the growth of A549 non-small cell lung 
adenocarcinoma cells (IC50=879.52 ± 22.55 μg/ml) in the MTT test and to have an 
inhibitory action against DNA topoisomerase I (topo I).
119
 In contrast though, peppermint 
extract was shown to be devoid of toxicity on human (HepG2/C3A) and mouse (MH1C1) 
hepatoma cells. In fact, it was concluded that peppermint leaf extract was useful as a 
negative control.
53
 Also, in B6C3F1 mice and Fischer 344 rats dosed for 103 weeks, with 
D/L-menthol it was concluded that it was not carcinogenic in either species.
85 
The peppermint constituent pulegone, is metabolized to piperitenone, piperitone, 
menthofuran, and menthone and these compounds are present in post-treatment urinary 
samples. As a consequence, pulegone, along with its main metabolites, were all tested for 
cytotoxicity in rat (MYP3) and human (1T1) urothelial cells using the MTT assay. 
Microscopic examination of the bladders from treated animals revealed superficial 
necrosis and exfoliation and there was an increased incidence of bladder neoplasms. It was 
deduced therefore that cytotoxicity followed by regenerative cell proliferation was at least 
theoretically responsible for pulegone-induced urothelial tumors in female rats .
120 
A study of peppermint on embryotoxicity during organogenesis in Balb/c mice did not 
reveal any evidence of a teratogenic effect even at doses up to 1200 mg/kg/day. However, 
fetal weights were decreased in the treatment group which was attributed either to 
15 
 
inhibition of cell growth via an inherent genotoxic effect or reabsorption of fetal 
extracellular fluid .
121 
In another study, the effect of natural Brazilian menthol was examined on a variety of 
pregnant species. These included mice (≤ 185 mg/kg/day on gestation days 6-15), rats (≤ 
218 mg/kg on gestation days 6 to 15), hamsters (≤ 405 mg/kg/day on days 6-10 of 
gestation) and artificially inseminated rabbits (≤ 425 mg/kg/day on gestation days 6 to 18). 
The study outcome conclusion was that menthol had no teratogenic effects and that it did 
not incite any fetotoxic abnormalities.
20 
 
Although pulegone produced a negative outcome in the Ames test,
122
 when given over a 
two-year period in mice (150 mg/kg by gavage) it yielded positive evidence of 
hepatoblastoma and hepatocellular carcinoma.
86
  By way of contrast, menthone generated 
a positive in the Ames test,
123
 but at a high dose, it did not produce any in vivo indication 
of a chronic pulmonary tumor response in mice.
124 
More recently, menthofuran proved to 
be negative in the Ames test
122
 and positive in the comet assay.
125
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Table 3. Mutagenicity, genotoxicity, carcinogenicity and developmental toxicity of 
peppermint and its constituents. 
Compound Test 
Animal species 
or bacterium 
Animal or 
cell culture 
strain 
Result 
(+/-) 
Reference 
Peppermint 
essential oil 
 
Ames test 
Escherichia coli WP2 uvrA 
 
- 
20,96 
 
Peppermint 
essential oil 
 
 
Ames test 
 
Salmonella 
typhimurium 
TA92, TA94, 
TA97 TA98, 
TA100, 
TA102, 
TA1535, 
TA1537, 
TA2637, 
G46 
 
 
 
- 
20,96 
Peppermint 
oil 
 
D/L-Menthol 
(150 µg/ml) 
 
Lymphoma 
mutation assay 
Mouse 
Lymphoma 
cells 
L5178Y 
tk+/- 
 
- 
97 
Peppermint 
leaf extract 
 
Teratogenicity 
test 
 
Mouse  
 
- 
121 
 
D/L- Menthol 
(1000 or 2000 
mg/kg) 
Replicative 
DNA synthesis 
test 
Mouse 
male 
B6C3F1 
mice and 
F344 rats 
 
+ 
111,112 
 
D/L Menthol 
Comet assay Mouse  
 
- 
 
111,112 
D/L Menthol 
Developmental 
toxicity 
 
Mouse  
 
- 
 
121 
 
D/L Menthol 
Developmental 
toxicity 
 
Rat, Mouse and 
Hamster 
 
 
 
- 
 
20 
 
      
17 
 
 
 
Pulegone 
 
 
Ames test 
 
 
Salmonella 
typhimurium 
TA100, 
TA1535   
≤10000 
μg/plate 
-  
122 
 
Pulegone 
 
Carcinogenicity 
urinary bladder 
and renal 
damage 
Rat  
 
+ 
86,120,125 
Pulegone 
 
Hepatoblastoma 
 
Hepatocellular 
carcinoma 
(≤150 mg/kg 
gavage x 2 
years) 
Mouse  + 86 
Menthone Ames test 
Salmonella 
typhimurium 
TA1537 + 123 
Menthone 
Pulmonary 
tumor response 
Mouse 
(4.75g/kg over 
24 weeks) 
 
 
- 
75,124 
Menthofuran 
Ames test 
 
Salmonella 
typhimurium 
TA100, 
TA1535 
≤10000 
μg/plate 
- 122 
Menthofuran Comet assay Rat  + 125 
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The European Medicines Agency
125
 has considered whether the tumors observed in animal 
experiments are meaningful for human risk assessment. Substantiated in sub-
chronic/chronic studies, organs of focus for pulegone as an example, are the liver and 
kidney.
86
 Moreover, sustained cytotoxicity plus cell proliferation induced by reactive 
cytotoxic metabolites rather than genotoxicity appear to be underlying neoplastic 
mechanisms.
125
 Thus, in the case of pulegone, long-term clinically non-relevant doses and 
continuous exposure are needed to incite neoplasms in rodents.
125
 Consequently, the 
committee on herbal medicinal products (CHMP) has recommended a pulegone exposure 
limit of 0.75 mg/kg body weight per day. 
 
3.6. Clinical studies and case reports on the side effects of peppermint and its related 
compounds.  
In a clinical investigation performed in the 1980s subjects were exposed to 1.0 g of 
menthol crystal vapor for 5 minutes after which they experienced a well-documented cold 
sensation in the nasal passages and the familiar perception of improved airflow.
126
 In 
addition, high doses of menthol are capable of inducing abdominal pain, convulsions, 
nausea, ataxia, drowsiness and coma.
127
 On top of this, menthol has also been shown to 
cause adverse effects on the CNS (ataxia, euphoria, nystagmus and diplopia) as described 
in a case report on a young teenager who inhaled 200 mg of menthol.
128
 On a similar note, 
in children younger than one year of age, intranasal administration of menthol is known to 
cause apnea, laryngeal and bronchial spasms and acute respiratory distress probably 
mediated by a reaction of the trigeminal nerve.
127,129-131
  
In dermatitis tests on patients who received various concentrations of peppermint oil, there 
was some positive hypersensitivity.
20,61,132
 In contrast, a triple-blind clinical trial on 96 
pregnant women with pruritus gravidarum who took 60 ml of peppermint oil twice per day 
for 2 weeks displayed no adverse effects.
133
 Similarly, in pediatric patients with irritable 
bowel syndrome who consumed 180 mg peppermint oil orally, no adverse effects were 
observed.
134
  
Several studies have been conducted concerning the effects of different doses of 
peppermint in patients leading up to a variety of conditions such as: orofacial 
granulomatosis, lichenoid eruptions of the oral mucosa, eczema on the hands and 
sensitization to tixocortol pivalate, allergic contact dermatitis, allergic contact cheilitis of 
the lips and perioral skin, dyspnea, recurrent irritant rash and even induction of IgE 
mediated systemic anaphylaxis. The majority of these ailments occurred as a result of a 
positive allergic reaction to peppermint, often accompanied by erythema and topical 
sensitivity.
135-143
  
Menthone administered to rats at a high dose over 28 days did display some signs of 
hepatotoxicity and cerebellar histopathology.
66,144
 However, as mentioned previously, the 
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significance of this finding may warrant careful interpretation. Pulegone and menthofuran 
are present in the herb pennyroyal, and their effects are often extrapolated from this 
source. Both compounds in this respect are thought to be abortifacient
67,145,146
 and 
menthofuran causes contact dermatitis as well as urticarial.
147,148
  
 
3.7. Contraindications, side effects and drug interactions related to peppermint and 
its constituents. 
  
Menthol administered for 28 days (≤ 800 mg/kg) in rats caused hepatocellular changes 
(vacuolization of hepatocytes) and pulegone (≤ 160 mg/kg) has also not only been 
reported to be hepatotoxic but neurotoxic as well. Consequently, it caused weight loss, 
atonia, decreased blood creatinine, histopathological changes in the liver and also in the 
white matter of the cerebellum.
149
 Menthone (≤ 800 mg/kg orally) on the other hand, dose 
dependently  decreased plasma creatinine, but increased alkaline phosphatase and bilirubin 
along with liver and spleen weights.
66 
In a later study examining peppermint constituents 
for their possible induction of the encephalopathy, one-month treatment with limonene 
(≤1600 mg/kg) or 1,8-cineole (1000 mg/kg) produced an accumulation of protein droplets 
containing α2µ globulin in proximal tubular epithelial cells but no encephalopathy in 
rats.
150
  
Peppermint and menthol have both been shown to possess Ca
2+
 channel blocking 
properties which may underlie their mechanism of efficacy against irritable bowel 
syndrome in the clinic.
151
 However, in some patients, the use of peppermint is 
accompanied by oral symptoms like burning mouth syndrome and oral ulceration.
152-154
 
Also in this context, direct application of peppermint oil to the chest or nasal area of 
infants is not recommended due to the risk of apnea, bronchial and/or laryngeal spasms .
9
 
Peppermint essential oil also is contraindicated in patients with bile duct obstruction, gall 
bladder inflammation and liver disorders .
109
 A further adverse effect has been detailed in 
rats receiving high dose peppermint tea (20g/L) where there were increased follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) levels but decreased total 
testosterone concentrations.
155
  
Peppermint oil can cause heartburn or perianal irritation, bradycardia and muscle tremor, a 
hypersensitivity reaction, contact dermatitis, abdominal pain and jaundice in newborn 
babies.
7,152,156-162
 (Olowe and Ransome-Kuti, 1980; Parys, 1983; Familusi and Dawodu, 
1985; Nash et al., 1986; Lawson, 1988; Wilkinson and Beck, 1994; Sainio and Kanerva, 
1995; Rita and Animesh, 2011; Milqvist et al., 2013). What is more, a study on a 58 year 
old woman who smoked menthol cigarettes also established that she suffered from 
gastrointestinal upsets with occasional vomiting, hand tremor, mental confusion and 
depression which were all ascribed to menthol.
109
 (Table 4). Similarly, in another case 
report, a 40-year-old woman with asthma and no history of asthma or any other forms of 
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allergy, presented with dyspnea, wheezing and nasal symptoms after using menthol 
containing candies and toothpaste.
163
  
There are numerous types of herbal medicine-drug interactions.
164
 One of the most 
prevalent types of interaction occurs between herbal products and drug metabolizing 
enzyme systems, particularly the cytochrome P450 isoenzymes (CYP). In essence, CYP 
isoenzymes play a major role in the phase I metabolism of certain drugs. Peppermint oil 
does interact with cytochrome P450 isoforms (for example: CYP1A2/2C8/2C9/2C19/2D6 
and 3A4) and therefore it may well modify the levels of drugs metabolized by those 
particular cytochromes.
165
 A case in point is afforded by peppermint essential oil 
preventing cytochrome P450 izoenzyme 3A (CYP3A) activity in rat and human liver 
microsomes thus inhibiting cyclosporine metabolism in vitro.
166
 Hence this type of 
peppermint interaction is capable of imposing a meaningful impact on drug effectiveness 
in the clinic. 
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Table 4. Case reports on the side effects of peppermint and its main constituents. 
Compound Species Main side effect Reference 
 
Peppermint essential oil 
 
 
Human 
 
Vital signs disrupted ≤ 
8 hours and 
unconscious ≤ 24 hours 
 
70 
 
 
Menthol 
 
 
Human 
Pain and cold 
hyperalgesia 
(at 40% concentration), 
ataxia and coma 
72,87167,168 
 
 
 
Menthol 
 
Rat 
Hepatocellular changes 
(200, 400, 800 mg) for 
28 days 
149 
 
Pulegone 
 
 
Human 
Abortefacient, fatality 
(present in Pennyroyal) 
Serum concentration = 
18 ng/ml 
67,145,146 
 
Pulegone 
 
Rat 
Weight loss, atonia, 
decreased blood 
creatinine content 
(Dose = 80, 160 mg) 
for 28 days 
149 
 
Menthone 
 
Rat 
Increased alkaline 
phosphatase, decreased 
creatinine, increased 
bilirubin and liver and 
spleen weights. 
NOEL = 200 mg/kg       
bw/day. (Dose ≤ 800 
mg/kg for 28 days) 
66 ,144 
 
 
Menthofuran 
 
Human 
 
Abortefacient, fatality 
(present in Pennyroyal) 
(Serum concentration = 
1-40 ng/ml) 
67,145 
 
Menthofuran 
 
Human 
Allergic contact 
dermatitis (erythema, 
vesiculation, edema). 
Contact urticaria. 
(present in Pennyroyal) 
147,148 
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Peppermint essential oil formulated as enteric-coated capsules has been shown to be well 
tolerated and effective against irritable bowel syndrome.
169
 Peppermint is also a risk 
factor for gastroesophageal reflux disease (GERD)
170
 and lifestyle changes including 
reduced peppermint intake have been recommended by the American College of 
Gastroenterology.
171
 In respect of this, peppermint essential oil, not only stimulates bile 
fluid secretion but may be involved in upregulating the bile acid synthesis‐related gene, 
cholesterol 7α‐hydroxylase (CYP7A1), and the nuclear bile acid receptor FXR (farnesoid 
X receptor) mRNA.
172
  
It has been shown that the terpene preparation Rowachol, which contains menthol and 
menthone,
173
 has cholelitholytic activity and its use has been recommended with careful 
monitoring for potential complications during cholesterol gallstone treatment.
174
 A 
mechanism underlying Rowachol activity may derive from a combination of its 
cholelitholytic, choleretic and spasmolytic properties which would tend to facilitate the 
passage of common bile duct gallstones.
174
  
 
4. Conclusion 
Peppermint has noteworthy pharmacological effects and therapeutic uses, but side effects 
and drug interactions have been reported in the literature. In this review, we categorized 
the conceivable toxicological effects of peppermint and its main components via data 
bases to identify relevant scientific sources.  
Various meaningful side effects of peppermint include heartburn or perianal irritation, 
bradycardia and muscle tremor, a hypersensitivity reaction, contact dermatitis, and 
abdominal pain.
154
 Based on its reported LD50 values (≤ 2000 mg/kg in rodents)
24
, 
peppermint may be categorized as moderately toxic.  
In respect of animal studies, peppermint and its component menthol isomers are devoid of 
any consequential mutagenicity, genotoxicity or embryotoxicity (Table 3). Be that as it 
may, peppermint does display carcinogenic effects such as lung and kidney cancers 
besides hepatocellular carcinoma at higher doses in mice. Furthermore, peppermint 
essential oil has a cytotoxic effect on human lymphocytes and some studies have disclosed 
that the oil is contraindicated in patients with, gall bladder inflammation and liver 
disorders.
109
  
There is evidence that peppermint oil interacts appreciably with cytochrome P450 
isoenzymes to reduce or prevent their activity in rat and human liver microsomes and this 
has a notable clinical impact on drug metabolism.
165
 In view of the possibility of the toxic 
side effects and the potential for drug interactions with peppermint highlighted in this 
review, it must be a consideration that this herbal medicine is used with clinical caution. 
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